MRA Advisory Group Reduces Holdings in Bristol Myers Squibb Company $BMY

Key Points

• MRA Advisory Group cut its Bristol Myers Squibb stake by 76.1% in the third quarter, selling 18,006 shares and retaining 5,646 shares valued at approximately $352,000.
• Other major institutional investors, including BlackRock and State Street, increased their positions, while institutional investors collectively own 76.41% of BMY’s shares.
• Bristol Myers Squibb reported quarterly EPS of $2.04, exceeding estimates, and declared a quarterly dividend of $0.63, representing a 4.2% annualized yield. Analysts maintain a “Moderate Buy” consensus rating with a $67.06 average price target.

MRA Advisory Group cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 76.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,646 shares of the biopharmaceutical company's stock after selling 18,006 shares during the quarter. MRA Advisory Group's holdings in Bristol Myers Squibb were worth $352,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $1,436,115,000. Legal & General Group Plc bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $980,862,000. BlackRock Inc. raised its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. State Street Corp boosted its position in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Bristol Myers Squibb by 153.8% in the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company's stock valued at $540,393,000 after acquiring an additional 5,399,407 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Transactions at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Price Performance

BMY traded up $0.17 during midday trading on Wednesday, hitting $59.77. The company had a trading volume of 5,291,411 shares, compared to its average volume of 11,979,384. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a market capitalization of $122.08 billion, a PE ratio of 13.14, a P/E/G ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm's 50-day simple moving average is $64.45 and its 200-day simple moving average is $60.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Morgan Stanley restated an "underweight" rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday. Guggenheim reaffirmed a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Royal Bank Of Canada increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Leerink Partners lowered shares of Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $73.00 to $59.00 in a report on Monday. Finally, Citigroup reissued a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $67.06.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.